f Vorasidenib: A Milestone in Targeted Therapy for IDH-Mutant Lower Grade Gliomas - Efficacy, Emerging Safety Concerns, and the Call for Comprehensive Safety Evaluation

References

1. BergerT.R. WenP.Y. Lang-OrsiniM. ChukwuekeU.N. World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas.JAMA Oncol.20228101493150110.1001/jamaoncol.2022.2844 36006639
   [Google Scholar]
2. MellinghoffI.K. Penas-PradoM. PetersK.B. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial.Clin. Cancer Res.202127164491449910.1158/1078‑0432.CCR‑21‑0611 34078652
   [Google Scholar]
3. BombinoA. MagnaniM. ContiA. A promising breakthrough: The potential of Vorasidenib in the treatment of low-grade glioma.Curr. Mol. Pharmacol.202417e1876142929032710.2174/0118761429290327240222061812 38425121
   [Google Scholar]
4. MellinghoffI.K. van den BentM.J. BlumenthalD.T. Vorasidenib in IDH1 or IDH2-mutant low-grade glioma.N. Engl. J. Med.2023389758960110.1056/NEJMoa2304194 37272516
   [Google Scholar]
5. FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.2024Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vorasidenib-grade-2-astrocytoma-or-oligodendroglioma-susceptible-idh1-or-idh2-mutation
6. Highlights of prescribing information Voranigo® (Vorasidenib).2024Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf